Lichen China
LICN
3 hedge funds and large institutions have $72.7K invested in Lichen China in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$41.7K |
| 2 |
CD
Chapin Davis
Baltimore,
Maryland
|
+$30.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.96K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Two Sigma Investments
New York
| $37.5K | +$41.7K | +89 | New |
|
|
CD
2
Chapin Davis
Baltimore,
Maryland
| $28K | +$30.9K | +66 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $7.31K | +$7.96K | +17 | New |
|
LICN Hedge Fund Activity: Q1 2023 in Review
3 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q1 2023, worth a combined $72.7K.
Buyers outnumbered sellers: 3 funds opened new LICN positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $41.7K.
- 3 institutional investors held Lichen China (LICN) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $72.7K of Lichen China stock for Q1 2023.
- 3 funds opened new Lichen China positions in Q1 2023 and 0 closed out, a net change of +3 holders.
- The largest Lichen China buyer in Q1 2023 was Two Sigma Investments, an estimated $41.7K added.
Based on aggregated 13F filings for Q1 2023.